Breye Therapeutics is a clinical development stage company that developing new therapies within Opthalmology
The lead program is Danegaptide – an oral drug that can both treat Diabetic Retinopathy and prevent disease progression. Danegaptide can stabilize cell-cell junctions in the retinal capillaries, protect from capillary loss, and prevent vascular leakage and edema.
Location: Copenhagen, Denmark
Sound contact: Johan Kördel (Board Director) and Thomas Tan (Board Observer)
News: Breye Therapeutics Strengthens Management Team and Board
News: Sound Bioventures seeds Breye Therapeutics
Read an interview with Ulrik Mouritzen, CEO and Founder A visionary journey to innovate sight-preserving therapies
Web: www.breye.com
